Beauty Health (NASDAQ:SKIN – Get Free Report)’s stock had its “buy” rating restated by equities researchers at Benchmark in a report released on Wednesday, Benzinga reports. They currently have a $23.00 target price on the stock. Benchmark’s target price points to a potential upside of 237.74% from the stock’s previous close.
A number of other equities analysts also recently issued reports on SKIN. Piper Sandler dropped their price target on Beauty Health from $17.00 to $15.00 in a research note on Thursday, June 15th. TD Cowen reduced their price target on shares of Beauty Health from $15.00 to $9.00 and set an “outperform” rating for the company in a research report on Thursday, August 10th. Stifel Nicolaus downgraded shares of Beauty Health from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $17.00 to $10.00 in a report on Tuesday, June 20th. Canaccord Genuity Group reaffirmed a “buy” rating and set a $10.00 target price on shares of Beauty Health in a report on Friday, August 25th. Finally, DA Davidson dropped their price target on shares of Beauty Health from $35.00 to $16.50 and set a “buy” rating on the stock in a research note on Thursday, August 10th. Three research analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $14.28.
Beauty Health Trading Up 0.7 %
SKIN stock traded up $0.05 during trading on Wednesday, hitting $6.81. 557,686 shares of the company traded hands, compared to its average volume of 1,862,887. The company has a 50-day moving average of $7.21 and a 200-day moving average of $9.50. The company has a debt-to-equity ratio of 4.55, a quick ratio of 7.98 and a current ratio of 9.28. Beauty Health has a 1 year low of $5.28 and a 1 year high of $14.00. The firm has a market capitalization of $904.95 million, a PE ratio of -48.36 and a beta of 1.17.
Beauty Health (NASDAQ:SKIN – Get Free Report) last posted its earnings results on Wednesday, August 9th. The company reported $0.03 EPS for the quarter, missing the consensus estimate of $0.05 by ($0.02). Beauty Health had a negative return on equity of 3.84% and a negative net margin of 3.83%. The company had revenue of $117.50 million during the quarter, compared to analysts’ expectations of $114.89 million. During the same period in the prior year, the business posted ($0.09) earnings per share. The company’s revenue for the quarter was up 13.5% on a year-over-year basis. Analysts predict that Beauty Health will post 0.03 earnings per share for the current fiscal year.
Insider Activity at Beauty Health
In related news, Chairman Brent L. Saunders bought 59,380 shares of the business’s stock in a transaction dated Wednesday, August 16th. The shares were purchased at an average price of $6.10 per share, with a total value of $362,218.00. Following the transaction, the chairman now owns 5,827,453 shares in the company, valued at approximately $35,547,463.30. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, CFO Michael P. Monahan bought 5,000 shares of the company’s stock in a transaction on Thursday, August 17th. The shares were acquired at an average cost of $6.02 per share, for a total transaction of $30,100.00. Following the purchase, the chief financial officer now directly owns 358,107 shares of the company’s stock, valued at $2,155,804.14. The purchase was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Chairman Brent L. Saunders acquired 59,380 shares of the stock in a transaction that occurred on Wednesday, August 16th. The stock was acquired at an average cost of $6.10 per share, with a total value of $362,218.00. Following the completion of the purchase, the chairman now owns 5,827,453 shares of the company’s stock, valued at $35,547,463.30. The disclosure for this purchase can be found here. In the last quarter, insiders acquired 97,380 shares of company stock valued at $593,948. Insiders own 41.70% of the company’s stock.
Institutional Trading of Beauty Health
A number of institutional investors and hedge funds have recently added to or reduced their stakes in SKIN. Tower Research Capital LLC TRC boosted its position in Beauty Health by 172.2% during the second quarter. Tower Research Capital LLC TRC now owns 6,666 shares of the company’s stock worth $56,000 after purchasing an additional 4,217 shares in the last quarter. State of Wyoming increased its holdings in Beauty Health by 46.4% in the 4th quarter. State of Wyoming now owns 6,791 shares of the company’s stock worth $62,000 after acquiring an additional 2,152 shares in the last quarter. Federated Hermes Inc. acquired a new position in Beauty Health during the first quarter worth $83,000. Levin Capital Strategies L.P. purchased a new position in Beauty Health during the second quarter valued at $84,000. Finally, Royal Bank of Canada grew its position in shares of Beauty Health by 22.8% in the third quarter. Royal Bank of Canada now owns 7,700 shares of the company’s stock valued at $91,000 after purchasing an additional 1,430 shares during the period.
Beauty Health Company Profile
The Beauty Health Company designs, develops, manufactures, markets, and sells aesthetic technologies and products worldwide. The company’s flagship product includes HydraFacial that enhance the skin to cleanse, extract, and hydrate the skin with proprietary solutions and serums. Its products also comprise Syndeo, a HydraFacial Delivery System designed to elevate every part of the treatment and connects providers to the consumer’s preferences to create a more personalized experience; HydraFacial Nation App, an app that allows consumers to learn about their skin health, discover treatment options, and track their treatments over time; and Keravive, a treatment for scalp health.